INTRODUCTION

48
The possibility to manage microbial infections through nanomedicine is a hot topic in 49 and whether this response is affected by the presence of 8 both saccharide antigens from diverse bacterial serotypes loaded onto the same 9 10 nanoparticle.The main goal of this study was to determine whether these GNPs could 11 induce specific antibodies against both CPSsofpneumococcalserotypes14or19F or to 12 13 affect the immune activity of one of them. We found that the bi-antigenic GNPs 14 induced anti-Pn14PS IgG antibodies titers of the same order of magnitude of the currently 15 16 used PCV13 human vaccine.
17
MATERIALS & METHODS 18 19
Synthesis of the ligands (neoglycoconjugates and T-helper peptide). 20 21
In order to prepare our new GNPs as a fully synthetic carbohydrate vaccine candidate, the 22 selected components (carbohydrate antigens and T-helper peptide) must be derivatized as 23 24
thiol-ending ligands in order to be efficiently conjugated to the gold nanocarrier, taking Briefly, serially diluted sera from immunized animals were incubated for 1 h at 37 °C in 8 flat-bottom plates, coated with 100 µl of purified Pn14PS or Pn19FPS (5 µg/mL). After 9 10 coating, the plates were blocked with 3% gelatin, then washed and horseradish 11 peroxidase-conjugated goat anti-mouse IgG was added and incubated for 1 h at 37 °C. Figure 3 for GNP-1. NMR was used to 25 26 qualitatively assess the presence of organic components at the gold surface. 
Immunological evaluation 35 36
Specific antibodies against Pn14PS, Pn19FPS, and Pn23FPS were measured in the 37 sera of immunized mice with a series of GNPs using ELISA. Quil-Awasco-delivered 38
39
As adjuvant during primary, but not upon booster immunization. 
48
In addition, we did not detect any specific IgG antibodies against native Pn19FPS and 49 50
Pn23FPS (the control polysaccharide coated plate) from the sera of immunized mice 51 with all GNPs except for the sera of mice immunized with PVC13 vaccine (Figure 4) . 52 53
IgG subclasses against Pn14PS antigen were also detected after the booster 54 immunization had been given at week 5 (Fig. S6, Supplementary Material) . GNP-1 55 56 57 58 59 1 2 3 4 5 6 7 immunization was found to evoke higher levels of anti-Pn14PS IgG-1, IgG-2a, and 8
IgG2b antibodies subclasses than other GNPs antigens. This data suggests that GNP-9 10 1 ensures a better antigen presentation than other GNPs.
11
The antibody response to the GNPs was also determined by using GNPs loaded with 12 13
Tri-19F (GNP-2) or Tetra-14 (GNP-4) as coating antigens in ELISA assays. W e 14 observed that the sera of mice immunized with GNP-1, GNP-2, and GNP-3 elicited 15 anti-19F antibody, even if with affinity and potency lower than the native polysaccharide. 11
The orientation of the aminopropyl linker did not appear to affect the affinity of the 12 13 saccharide for antibody binding (IC50 7.44 x 10 -2 and 2.61 x 10 -2 mg/mL for 3α and 3β, 14 respectively) suggesting the anomeric mixture can be used in the present study without 15 16 additional purification steps (see Table S2 , Supplementary Material). 32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 https://mc04.manuscriptcentral.com/fm-nnm 34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
GENERAL METHODS
5
All chemicals were purchased as reagent grade from Sigma-Aldrich, except for 6 7 chloroauric acid (Strem Chemicals), and were used without further purification. with an internal width of 45mm were used. All UV/Vis spectra were subtracted 33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 https://mc04.manuscriptcentral.com/fm-nnm Synthesis of thiol-ending ligand. Figure S1 . Thiol-ending conjugates used for the preparation of GNPs. GenScript Corp (Piscataway, NJ, USA) and a single batch was used throughout the 40 study.
42
The thiol-ending conjugate 2 of the tetrasaccharide antigen related to serotype 14, conditions (Scheme S1). 
N-(benzyloxycarbonyl)-3-amminopropyl (2-acetamido-3-O-benzyl-4,6-O-benzylidene
Compound 5 (90 mg, 0.07 mmol, 1 eq.) and N-(benzyloxycarbonyl)-3- necessary amount of pure 7-α and 7-β in order to obtain, after hydrogenolysis,
23
3-α and 3-β for Elisa assays ( Figure S2 ). 
3-Aminopropyl 2-acetamido-2-deoxy-β -D-mannopyranosyl-(1→4)-α-D-
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